{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:44:22Z","timestamp":1740159862179,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s13318-023-00818-8","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T07:04:18Z","timestamp":1678345458000},"page":"257-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients\u00a0with Neurogenic Detrusor Overactivity"],"prefix":"10.1007","volume":"48","clinical-trial-number":[{"clinical-trial-number":"nct00857896","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01557244","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5512-2190","authenticated-orcid":false,"given":"Yamato","family":"Sano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Darekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimal K","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"818_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0022-5347(06)00305-3","volume":"176","author":"T Neveus","year":"2006","unstructured":"Neveus T, von Gontard A, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children\u2019s Continence Society. J Urol. 2006;176:314\u201324.","journal-title":"J Urol"},{"key":"818_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/nau.24211","volume":"39","author":"R Stein","year":"2020","unstructured":"Stein R, Bogaert G, Dogan HS, et al. EAU\/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. Neurourol Urodyn. 2020;39:45\u201357.","journal-title":"Neurourol Urodyn"},{"key":"818_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40272-017-0249-x","volume":"19","author":"P Kroll","year":"2017","unstructured":"Kroll P. Pharmacotherapy for pediatric neurogenic bladder. Paediatr Drugs. 2017;19:463\u201378.","journal-title":"Paediatr Drugs"},{"key":"818_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/nau.22751","volume":"35","author":"PF Austin","year":"2016","unstructured":"Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children\u2019s Continence Society. Neurourol Urodyn. 2016;35:471\u201381.","journal-title":"Neurourol Urodyn"},{"key":"818_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0090-4295(02)01793-4","volume":"60","author":"SB Bauer","year":"2002","unstructured":"Bauer SB. Special considerations of the overactive bladder in children. Urology. 2002;60:43\u20138.","journal-title":"Urology"},{"key":"818_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00467-007-0691-z","volume":"23","author":"C Verpoorten","year":"2008","unstructured":"Verpoorten C, Buyse GM. The neurogenic bladder: medical treatment. Pediatr Nephrol. 2008;23:717\u201325.","journal-title":"Pediatr Nephrol"},{"key":"818_CR7","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00467-008-0780-7","volume":"23","author":"TP de Jong","year":"2008","unstructured":"de Jong TP, Chrzan R, Klijn AJ, et al. Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol. 2008;23:889\u201396.","journal-title":"Pediatr Nephrol"},{"key":"818_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.5414\/CPP46556","volume":"46","author":"B Malhotra","year":"2008","unstructured":"Malhotra B, Guan Z, Wood N, et al. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008;46:556\u201363.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"818_CR9","unstructured":"Pfizer Inc. Toviaz\u00ae (fesoterodine fumarate). Full prescribing information. New York: Pfizer Inc.; 2021."},{"key":"818_CR10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jpurol.2012.02.008","volume":"8","author":"B Malhotra","year":"2012","unstructured":"Malhotra B, El-Tahtawy A, Wang E, et al. Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder. J Pediatr Urol. 2012;8:336\u201342.","journal-title":"J Pediatr Urol"},{"key":"818_CR11","doi-asserted-by":"publisher","unstructured":"Kitta T, Darekar A, Malhotra B, et al. Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: a 24-week, randomized, open-label, phase 3 study. J Pediatr Urol. 2022;22:S1477-5131. https:\/\/doi.org\/10.1016\/j.jpurol.2022.11.020.","DOI":"10.1016\/j.jpurol.2022.11.020"},{"key":"818_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0022-5347(17)54449-3","volume":"126","author":"EJ McGuire","year":"1981","unstructured":"McGuire EJ, Woodside JR, Borden TA, et al. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126:205\u20139.","journal-title":"J Urol"},{"key":"818_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0022-5347(17)38389-1","volume":"145","author":"NT Galloway","year":"1991","unstructured":"Galloway NT, Mekras JA, Helms M, et al. An objective score to predict upper tract deterioration in myelodysplasia. J Urol. 1991;145:535\u20137.","journal-title":"J Urol"},{"key":"818_CR14","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, et al. NONMEM 7.4 user\u2019s guides (1989\u20132018). https:\/\/nonmem.iconplc.com\/nonmem743\/guides. Accessed 26 July 2022."},{"key":"818_CR15","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021. https:\/\/www.R-project.org\/. Accessed 26 July 2022."},{"key":"818_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Progr Biomed. 2005;79:241\u201357.","journal-title":"Comput Methods Progr Biomed"},{"key":"818_CR17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/jcph.274","volume":"54","author":"M Oishi","year":"2014","unstructured":"Oishi M, Tomono Y, Yamagami H, et al. Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations. J Clin Pharmacol. 2014;54:928\u201336.","journal-title":"J Clin Pharmacol"},{"key":"818_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351.","journal-title":"AAPS J"},{"issue":"180","key":"818_CR19","first-page":"e1","volume":"16","author":"I Franco","year":"2020","unstructured":"Franco I, Hoebeke P, Baka-Ostrowska M, et al. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. J Pediatr Urol. 2020;16(180):e1-8.","journal-title":"J Pediatr Urol"},{"key":"818_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/01.ju.0000147813.28822.d2","volume":"173","author":"I Franco","year":"2005","unstructured":"Franco I, Horowitz M, Grady R, et al. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. J Urol. 2005;173:221\u20135.","journal-title":"J Urol"},{"key":"818_CR21","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/nau.21081","volume":"30","author":"T Frenkl","year":"2011","unstructured":"Frenkl T, Railkar R, Palcza J, et al. Variability of urodynamic parameters in patients with overactive bladder. Neurourol Urodyn. 2011;30:1565\u20139.","journal-title":"Neurourol Urodyn"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00818-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-023-00818-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00818-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T10:24:39Z","timestamp":1683800679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-023-00818-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1007\/s13318-023-00818-8","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"6 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer Inc. All authors are employees and shareholders of Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees and shareholders of Pfizer Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Upon request, and subject to certain criteria, conditions and exceptions (see  for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The NONMEM code is in Online Resource 4 and Online Resource 5. The R code for the simulation describing the assessment of the impact of body weight on MCC is in Online Resource 6. Other R codes used to generate the graphics can be obtained from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"YS analyzed the data. All authors made substantial contributions to the interpretation of data and participated in drafting and critically revising the work. All authors approved the final version to be published and agree to be accountable for all aspects of the work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The study protocols were approved by the institutional review boards\/ethics committees of the study sites, and all participants provided written informed consent before participation in the studies. The studies were conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and conducted according to the International Conference on Harmonization Guidelines for Good Clinical Practice.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent before participation in the studies.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"These analyses included data from the following studies: NCT00857896 and NCT01557244","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial Registration"}}]}}